DxDiscovery is awarded an SBIR Phase IIB grant for development of rapid pertussis (Whooping cough) diagnostic
Prompt diagnosis of early pertussis (Whooping cough) is critical for minimizing the extent and economic burden of pertussis outbreaks. Specifically, timely contact tracing and deployment of prophylactic antibiotics to high-risk close contacts depends on the swift diagnosis of pertussis cases. Rapid diagnosis of pertussis also facilitates antibiotic (more…)Read More
DxDiscovery is awarded an SBIR Phase II contract for development of an immunoassay diagnostic for coccididioidomycosis
Coccidioidomycosis is a serious form of fungal pneumonia that predominantly affects people who visit or live in the southwest United States and northern Mexico. Within the endemic zone, it can be extremely common. Current diagnostics for coccidioidomycosis include fungal culture, microscopy, and serology (detection of patient antibodies). (more…)Read More
DxDiscovery is awarded defense funding, through a multi-institute collaboration, for the development of small molecule-based detection assay.
The design of rapid assays, such as lateral flow immunoassays (LFI), rely heavily on antibodies for antigen detection. While the antibodies used in these assays are highly specific to the antigen of interest, the generation of reagents necessitates the use of animals and is time intensive. A novel rapid assay that replaces antibodies with (more…)Read More
NIH awards DxDiscovery a Phase II SBIR for development of a rapid diagnostic for tinea capitis and onychomycosis
Tinea capitis (scalp ringworm) is a serious fungal infection that affects 3-8% of children in the United States. Children from disadvantaged socioeconomic backgrounds, sub-Saharan African descent, or other groups that have been traditionally disadvantaged within the health care system are most at risk of infection. (more…)Read More
NIH awards DxDiscovery a Phase I SBIR for development of Immunoassay for early diagnosis of mucormycosis
Mucormycosis is a devastating invasive fungal infection that has a 47% or greater mortality rate. It predominantly affects immunocompromised individuals, including bone marrow or solid organ transplant recipients, patients with hematological malignancies undergoing chemotherapy, and patients with diabetes mellitus. (more…)Read More
DxDiscovery receives pilot funding to develop a field-ready diagnostic for Citrus Greening
Huanglongbing (HLB) or citrus greening is a destructive disease of citrus worldwide and is associated with infection by the vector-borne bacterium Candidatus Liberibacter asiaticus (Ca. Liberibacter or CLas). HLB is now widespread in regions of Florida, California, Texas, Georgia, and Puerto Rico, resulting in significant financial implications. Immediate removal of the diseased tree followed by strict quarantine measures appear to be successful in the mitigation of the spread of HLB.
Common testing protocols, using qPCR, are cost prohibitive and routinely take weeks to months after sample collection for results to be made available, limiting on-site decision making. Pilot funding awarded to DxDiscovery and the University of Nevada, Reno by the California Citrus Board allowed for exploration into monoclonal antibody production against a CLas specific target, an initial step in the development of antigen-based detection assays.Read More
NIH awards DxDiscovery a Phase II SBIR for development of a rapid diagnostic for pertussis (whooping cough)
Pertussis (whooping cough) is rapidly re-emerging as a serious public health threat in the United States. Current diagnostics (PCR and culture) are slow, expensive and require a high level of user expertise. The goal of this project is to resolve a critical public health need for improved pertussis diagnostics by developing a point-of-care immunoassay that can diagnose early-stage pertussis in minutes, at very low cost, and without the need for specialized equipment or user expertise. (more…)Read More
Department of Defense awards DxDiscovery/University of Nevada, Reno $1M Sequential Phase II SBIR
DxDiscovery is continuing efforts to develop medical countermeasures against melioidosis and glanders. These diseases are caused by Burkholderia pseudomallei and Burkholderia mallei, respectively. B. mallei infections are rare, however, B. pseudoamallei infections are a significant cause of morbidity and mortality in southeast Asia.Read More
Point of Care immunoassay for early diagnosis of pertussis awarded.
National Institutes of Health , National Institute of Allergy and Infectious Disease award number R43AI109891 was awarded to Principal Scientist Amanda Burnham-Marusich and Thomas Kozel for development of a point of care immunoassay for early diagnosis of pertussis on June, 1st 2014.Read More
DxDiscovery begins work on an NIH-funded Phase I SBIR project to develop a rapid diagnostic for pertussis (whooping cough)
Pertussis (whooping cough) is a serious and potentially life-threatening respiratory disease caused by the bacterium Bordetella pertussis. Worldwide, 18.4 million people become ill with pertussis each year, and 254,000 of these patients die. Despite high vaccine coverage in the United States, there were still over 48,000 pertussis cases reported (more…)Read More